Next steps for the optimization of exon therapy for Duchenne muscular dystrophy
Open Access
- 21 January 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (2) , 133-143
Abstract
It is established that the exon-skipping approach can restore dystrophin in Duchenne muscular dystrophy (DMD) patients. However, dystrophin restoration levels are low, and the field is evolving to ...Keywords
This publication has 66 references indexed in Scilit:
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Systemic Administration of PRO051 in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2011
- Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse ModelMolecular Therapy, 2010
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogsAnnals of Neurology, 2009
- Antisense-mediated exon skipping: A versatile tool with therapeutic and research applicationsRNA, 2007
- Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomersCurrent Opinion in Pharmacology, 2005
- Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon SkippingScience, 2004
- Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cellsGene Therapy, 2004
- The U7 snRNP and the hairpin binding protein: Key players in histone mRNA metabolismSeminars in Cell & Developmental Biology, 1997